Prostate Cancer - Results from #140

Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy. February 20, 2025

CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer. February 20, 2025

Clarity Receives US FDA Fast Track Designation for the Treatment of Metastatic Castration-Resistant Prostate Cancer Patients with Cu-67 SAR-bisPSMA February 19, 2025

Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. February 19, 2025

Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders. February 19, 2025

Social risk factors screening preferences among breast and prostate cancer survivors: A qualitative study. February 19, 2025

Impact of Prostate Cancer Treatment on Quality of Life of LGBTQ+ Patients: A Systematic Review. February 19, 2025

Validation of the Barcelona Magnetic Resonance Imaging Predictive Model for Significant Prostate Cancer Detection in Men Undergoing Mapping per 0.5 Mm-Core Targeted Biopsies of Suspicious Lesions and Perilesional Areas. February 19, 2025

Effects on Quality of Life and Self-Efficacy of Instant Messaging Services in Self-Management Programs for Prostate Cancer: A Systematic Review and Meta-Analysis. February 19, 2025

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. February 18, 2025

Treatment switching between Enzalutamide and Abiraterone Acetate and time to oral opioid initiation in castration-resistant prostate cancer patients. February 18, 2025

The lived experience of active surveillance for prostate cancer: a systematic review and meta-synthesis. February 18, 2025

Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer. February 18, 2025

Mainstreaming improved adoption of germline testing for Veterans Affairs patients with metastatic prostate cancer without exacerbating disparities. February 18, 2025

PSA Density to Select MRI Targeted versus Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study. February 17, 2025

A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol. February 17, 2025

An Analysis of Print and Online Media's Representation of Prostate Cancer in Public Figure. February 17, 2025

Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer. February 17, 2025

Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening. February 17, 2025

Clinical and Imaging Predictors of False-Positive and False-Negative Results in Prostate Multiparametric MRI Using PI-RADS Version 2. February 17, 2025

Page 8 of 1466